GSK: to present its advances in HIV care
(CercleFinance.com) - GSK announces that ViiV Healthcare, its global HIV company, will present summaries of its HIV treatment and prevention portfolio and research pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) from 9 to 12 March in San Francisco.
In particular, we are sharing early data from our transformative pipeline, including results from our third-generation integrase inhibitor and partner assets, said Kimberly Smith, Head of R&D at ViiV Healthcare.
These assets have the potential to increase dosing intervals beyond what is currently available, with the aim of delivering what the HIV community tells us they want and need, she added.
The company will also present new data on Apretude (CAB LA for PrEP) in HIV prevention and Cabenuva (cabotegravir) + long-acting rilpivirine (CAB+RPV LA).
Copyright (c) 2025 CercleFinance.com. All rights reserved.
In particular, we are sharing early data from our transformative pipeline, including results from our third-generation integrase inhibitor and partner assets, said Kimberly Smith, Head of R&D at ViiV Healthcare.
These assets have the potential to increase dosing intervals beyond what is currently available, with the aim of delivering what the HIV community tells us they want and need, she added.
The company will also present new data on Apretude (CAB LA for PrEP) in HIV prevention and Cabenuva (cabotegravir) + long-acting rilpivirine (CAB+RPV LA).
Copyright (c) 2025 CercleFinance.com. All rights reserved.